Summary
Psoriatic arthritis (PSA) is an inflammatory arthritis associated with psoriasis. Although not considered an autoimmune process, there is evidence for humoral and cellular immune abnormalities similar to autoimmune diseases such as rheumatoid arthritis and systemic lupus (SLE). We investigated mitogen-induced proliferation and interleukin 2 (IL-2) production by peripheral blood mononuclear cells in patients with PSA. Both IL-2 production and proliferation were significantly decreased in PSA patients when compared to controls. Increased arachidonic acid metabolism has been reported in skin and peripheral mononuclear cells of patients with psoriasis and PSA. We therefore also investigated the effect of indomethacin and prostaglandin E2 (PGE2) on IL-2 production. Addition of indomethacin to cultures did not significantly change IL-2 production in patients with PSA, but did so in controls. PGE2 produced a significant reduction in IL-2 production in PSA and in controls.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Espinoza LR (1985) Psoriatic arthritis: further epidemiologic and genetic considerations. In: Gerber LH, Espinoza LR (eds) Psoriatic arthritis. Grune & Stratton, Orlando, p 9
Laurent MR, Panayi GS, Shepard P (1981) Circulating immune complexes, serum immunoglobins and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 40:66–99
Sany J, Clot J (1980) Immunologic abnormalities in psoriatic arthropathy. J Rheumatol 7:438–444
Leonard DG, O'Duffy JD, Rogers RS (1978) Prospective analysis of psoriatic arthritis patients hospitalized for psoriasis. Mayo Clin Proc 53:511–518
Espinoza LR, Gaylord SW, Vasey FB, Osterland CK (1979) Cell-mediated immunity in psoriatic arthritis. J Rheumatol 7:218–224
Rubins AY, Merson AG (1987) Subpopulations of T lymphocytes in psoriasis patients and their changes during immunotherapy. J Am Acad Dermatol 17:972–977
Gladman DD, Keystone EC, Schacter RK (1983) Aberration in T-cell subpopulations in patients with psoriasis and psoriatic arthritis. J Invest Dermatol 80:286–290
Smith MD, Roberts-Thompson PJ (1989) Interleukin 2 and interleukin 2 inhibitors in human serum and synovial fluid. II. Mitogenic stimulation, interleukin 2 production and interleukin 2 receptor expression in rheumatoid arthritis, psoriatic arthritis and Reiter's syndrome. J Rheumatol 16:897–903
Miyasaka N, Nakamura T, Russell IJ, Talal N (1984) Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunopathol 31:109–117
Kitas GD, Salmon M, Farr M, Gaston JSH, Bacon PA (1988) Deficient interleukin 2 production in rheumatoid arthritis: association with disease activity and systemic complications. Clin Exp Immunol 73:242–249
Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78
Gillis S, Ferm MM, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120:2027–2032
Bocchieri MH, Smith JB, Staruch NJ, Wood DD (1985) Functional consequence of perceived interleukin deficiencies? Analysis employing NZB X C58 recombinant inbred mice. Clin Exp Immunol 62:622–629
Emery P, Wood N, Gentry K, Stockman A, Mackay IR, Bernard O (1988) High affinity interleukin 2 receptors on blood lymphocytes are decreased during active rheumatoid arthritis. Arthritis Rheum 31:1176–1181
Ishida H, Kumagai S, Umehara H, Sano H, Tagaya Y, Yodoi J, Imura H (1987) Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol 139:1070–1074
Miossec P (1993) Interleukin 4. A potential anti-inflammatory agent. Rev Rheum 60:87–90
Holter W (1992) Regulation of interleukin 4 production and of interleukin 4 producing cells. Int Arch Allergy Immunol 98:273–278
Kragballe K, Voorhees JJ (1985) Arachidonic acid and leukotriens in pathogenesis and treatment. In: Roenigk HH, Malbach HI (eds) Psoriasis, Dekker, New York, pp 255–263
Lew W, Oppenhelm JJ, Matsushlama K (1988) Analysis of the supression of IL-1 alpha and IL-1 beta production in human peripheral blood mononuclear adherent cells by a glucocorticold hormone. J Immunol 140:1895–1902
Knudsen PJ, Dinarello CA, Strom TB (1986) Prostaglandins posttranscriptionally inhibit monocyte expression on interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 137:3189–3194
Chouaib S, Welte K, Mertelsmann R, Dupont B (1985) Prostaglandin E2 acts on two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down regulation of transferrin receptor expression. J Immunol 135:1172–1179
Walker C, Kristensen F, Bettens F, DeWeck AL (1983) Lymphokine regulation of activated (G1) lymphocytes. Prostaglandin E2 induced inhibition of interleukin 2 production. J Immunol 130:1770–1773
Rappaport RS, Dodge GR (1982) Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 155:943–948
Numo R, Lapadula G (1987) Present status and new perspectives in nonsteroidal anti-inflammatory drugs therapy, Scand J Rheumatol [Suppl] 66:75–83
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fort, J.G., Smith, J.B. & Abruzzo, J.L. Abnormal T-cell function in patients with psoriatic arthritis: evidence for decreased interleukin 2 production. Rheumatol Int 13, 151–154 (1993). https://doi.org/10.1007/BF00301262
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00301262